Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 10465182.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
C-reactive protein concentrations as a marker of inflammation predicts vascular risk and is raised in type-2 diabetes. In a 6-month double-blind placebo controlled trial, a combination of transdermal oestradiol 80 microg with continuous oral norethisterone 1 mg significantly reduced C-reactive protein concentrations in postmenopausal women with type-2 diabetes.
Medical subject headings
- C-Reactive Protein
- Diabetes Mellitus, Type 2
- Estrogen Replacement Therapy